Browsing Tag
Hercules Capital
6 posts
Heron Therapeutics (Nasdaq: HRTX) withdraws 2026 guidance as CINVANTI patent ruling reshapes plan
Heron Therapeutics withdrew 2026 guidance and cut $13.5m of Hercules debt after a June Delaware ruling on CINVANTI, with monthly covenants now running through 2027.
Dyne’s FORCE RNA therapy reversed muscle damage in mice, and its first FSHD trial is now cleared
DYNE-302 enters clinical development after FDA clearance as Dyne expands its FORCE pipeline following a $431.4 million equity raise.
Dyne Therapeutics (NASDAQ: DYN) slides as $375m stock sale resets valuation
Dyne Therapeutics strengthens launch funding, but its discounted $375 million share sale tests whether regulatory progress can outrun dilution pressure.
Replimune Group (NASDAQ: REPL) plans layoffs after FDA rejects Tudriqev again, forcing a biotech reset
Replimune plans layoffs after the FDA rejected Tudriqev again. Read what the setback means for REPL stock, cash runway, strategy, and rivals.
Behavox expands AI ecosystem with acquisition of Mosaic Smart Data
Behavox, a leading AI-driven insights company, has completed the acquisition of Mosaic Smart Data, a financial technology firm…
BridgeBio Pharma secures $299m in funding to accelerate genetic disease drug development
BridgeBio Pharma, a leading clinical-stage biopharma company specialising in treatments for genetic diseases, has raised $299.2 million in…